These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12032583)

  • 1. High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
    Ferrero B; Durelli L
    Neurol Sci; 2002 Apr; 23 Suppl 1():S9-24. PubMed ID: 12032583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
    Shibata-Hamaguchi A; Samuraki M; Furui E; Iwasa K; Yoshikawa H; Hayashi S; Yamada M
    Acta Neurol Scand; 2007 Dec; 116(6):406-8. PubMed ID: 17986100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.
    Gajdos P; Chevret S
    Ann N Y Acad Sci; 2008; 1132():271-5. PubMed ID: 18096850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic strategy in myasthenia gravis].
    Tranchant C
    Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis.
    Fuchs S; Feferman T; Meidler R; Margalit R; Sicsic C; Wang N; Zhu KY; Brenner T; Laub O; Souroujon MC
    J Neuroimmunol; 2008 Feb; 194(1-2):89-96. PubMed ID: 18178258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
    Gajdos P; Chevret S; Clair B; Tranchant C; Chastang C
    Ann Neurol; 1997 Jun; 41(6):789-96. PubMed ID: 9189040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experiences with high dosage immunoglobulin G in neuromuscular diseases].
    Schuchardt V; Hotz M; Hund E; Sun S; Heitmann R; Hacke W
    Nervenarzt; 1993 Feb; 64(2):98-103. PubMed ID: 8450901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies.
    Zinman L; Bril V
    Ann N Y Acad Sci; 2008; 1132():264-70. PubMed ID: 18567877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myasthenia gravis and myasthenic syndrome.
    Antozzi C
    Neurol Sci; 2003 Oct; 24 Suppl 4():S260-3. PubMed ID: 14598056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
    Gajdos P; Tranchant C; Clair B; Bolgert F; Eymard B; Stojkovic T; Attarian S; Chevret S;
    Arch Neurol; 2005 Nov; 62(11):1689-93. PubMed ID: 16286541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
    Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
    Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immune globulin in myasthenia gravis.
    Gajdos P
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose intravenous immunoglobulin treatment of multiple sclerosis.
    Durelli L; Isoardo G
    Neurol Sci; 2002 Apr; 23 Suppl 1():S39-48. PubMed ID: 12032586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunoglobulin therapy of neuromuscular diseases].
    Schuchardt V
    Nervenarzt; 1993 Feb; 64(2):91-7. PubMed ID: 8450900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyshidrotic eczema associated with the use of IVIg.
    Kotan D; Erdem T; Acar BA; Boluk A
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23417935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus.
    Aoyama Y
    J Dermatol; 2010 Mar; 37(3):239-45. PubMed ID: 20507387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
    Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The 2-phase action on mice of immunoglobulins isolated from the blood of a myasthenia patient].
    Smirnov VA; Saĭkova LA; Lobzin VS
    Biull Eksp Biol Med; 1988 Nov; 106(11):549-52. PubMed ID: 3196852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenic crisis: guidelines for prevention and treatment.
    Jani-Acsadi A; Lisak RP
    J Neurol Sci; 2007 Oct; 261(1-2):127-33. PubMed ID: 17544450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.